The ectonucleotidase CD39 identifies tumor-reactive CD8⁺ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.

ABSTRACT: Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies. CD39 expression is a promising surrogate of tumor-reactive CD8⁺ T cells. Here, we comprehensively profiled CD39 expression in human lung cancer. CD39 expression enriched for CD8⁺ T cells with features of exhaustion, tumor reactivity, and clonal expansion. Flow cytometry of 440 lung cancer biospecimens revealed weak association between CD39⁺ CD8⁺ T cells and tumoral features, such as programmed death-ligand 1 (PD-L1), tumor mutation burden, and driver mutations. Immune checkpoint blockade (ICB), but not cytotoxic chemotherapy, increased intratumoral CD39⁺ CD8⁺ T cells. Higher baseline frequency of CD39⁺ CD8⁺ T cell

SUBMITTER: Chow A 

PROVIDER: S-EPMC9887636 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature